Navigation Links
Covance Reports Fourth Quarter Revenue of $532M, GAAP EPS of $0.35, Pro Forma EPS of $0.73, and Adjusted Net Orders of $759M
Date:1/25/2012

ervices.  Net revenues for the fourth quarter of 2011 grew 10.0% year-on-year to $298.0 million, primarily driven by the continued strong performance in clinical development and a 190 basis point tailwind in foreign exchange.  On a sequential basis, revenues declined $5.0 million due to a $10.1 million foreign exchange headwind, which more than offset growth across the segment's service offerings, at constant exchange rates.

GAAP operating income for the fourth quarter was $58.2 million and included $1.3 million in costs associated with our restructuring actions. Pro forma operating income, excluding these costs, was $59.5 million, compared to $58.4 million last quarter and $54.7 million in the fourth quarter of the prior year. Pro forma operating margins, excluding these costs, were 20.0% for the fourth quarter of 2011 compared to 19.3% last quarter and 20.2% in the fourth quarter of last year. The sequential increase in profitability was primarily due to stronger central laboratory performance.

Corporate InformationThe Company's backlog at December 31, 2011 was $6.14 billion compared to $6.08 billion at September 30, 2011 and $6.19 billion at December 31, 2010. Foreign exchange negatively impacted sequential backlog growth by $75 million.  

Corporate expenses totaled $37.0 million in the fourth quarter of 2011 (including $2.7 million in restructuring costs) compared to $38.4 million last quarter (including $1.4 million in restructuring costs) and $39.9 million in the fourth quarter of last year.

During the fourth quarter, the company recorded a $12.1 million charge to recognize an impairment in the carrying value of an equity investment in a supplier of research products.  This charge is reflected as a component of other income (expense) in the consolidated statements of income.

Cash and cash equivalents at December 31, 2011 were $389 million compared to $400 million at September 30, 2011 and $377 million
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Covance Decides to Pursue Its Original Preclinical Strategy in China
2. Covance and Lilly Finalize 10-Year, $1.6 Billion Strategic R&D Collaboration
3. Covance Purchases Equity Stake in Caprion Proteomics
4. Covance Increases Early Clinical Footprint in Europe with Acquisition of Swiss-Based Early Clinical Development Site
5. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
6. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
7. Covance Reports First Quarter Revenue of $441M and EPS of $0.63; Updates Full Year Financial Targets
8. Covance Elects John McCartney to Companys Board of Directors
9. Covance to Present at the Drug Information Associations 45th Annual Meeting
10. Covance Appoints Dr. Steven M. Michael as Vice President and Chief Scientific Officer of Global Bioanalytical Services
11. Covance to Sell Its Interactive Voice and Web Response Services and Enter Into a Multi-Year Marketing Agreement with Phase Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... “We are honored to be named to this ... of Radiant Sage. “We are offering truly ground-breaking clinical ... market to a different level. We are enabling ... and effectively manage the massive amounts of medical imaging ... read by trained physicians. Being recognized by technology industry ...
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today announced that the ... 28, 2010 , after the market closes. The press release will be followed ... open to the public via telephone and webcast. During the conference call, the ... , , ...
... EXTON, Pa. , July 21 ViroPharma Incorporated,s (Nasdaq: VPHM ... Wednesday, July 28, 2010 before the open of the U.S. financial markets. , ... The company will host a conference call and live ... the conference call, ViroPharma management will discuss the 2010 second quarter financial results and ...
... RESEARCH TRIANGLE PARK, N.C. , July 21 Chimerix, ... it has expanded its clinical management team with the appointment of ... and Herve Mommeja-Marin, MD, as Vice President of Clinical Research.   ... In these ...
Cached Biology Technology:Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast 2ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 2Chimerix Appoints Two New Vice Presidents to Clinical Management Team 3
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014 /PRNewswire-iReach/ -- The ... hosting the 36 th Annual International Conference (EMBC,14), ... and Towers in Chicago, Illinois , ... than 2,500 global leaders, students, and industry professionals in ... Logo - http://photos.prnewswire.com/prnh/20140827/140333 ...
(Date:8/27/2014)... But every creature is a baby once. , A ... 24 very young dinosaurs and one older individual is ... caretaker, according to a new study by University of ... Dodson led the work, collaborating with researchers from China,s ... held. Hedrick is a doctoral student in the School ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... canary in the coal mine, penguins are sounding ... world,s oceans, and the culprit isn,t only climate ... Oil pollution, depletion of fisheries and rampant ... penguin species, along with Earth,s warming climate, are ...
... current standard practice of giving infants and children 100 ... deprivation may actually inflict additional harm, researchers at UT ... by oxygen deprivation, known as hypoxic-ischemic brain injury, is ... long-term neurological damage among infants and children. This can ...
... Twelve investigators have received grants totaling $5 million ... of food allergy, a significant public health concern. ... is funded by the National Institute of Allergy ... Institutes of Health, and two advocacy groups, the ...
Cached Biology News:Penguins setting off sirens over health of world's oceans 2Penguins setting off sirens over health of world's oceans 3Penguins setting off sirens over health of world's oceans 4Resuscitation technique after brain injury may do more harm than good 2NIAID announces grants to stimulate food allergy research 2NIAID announces grants to stimulate food allergy research 3
... a commonly used technique for studying protein ... electrophoresed on SDS-PAGE and transferred to a ... they are probed with specific antibodies. Unlike ... of Southern and Northern blots, it has ...
... Basic Package Superior Protein Detection and ... ProXPRESS 2D Proteomic Imaging System is a ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... Neutralizing synthetic peptide for OPA1-01009, OPEP-01009 is a 16 amino ... human DNA fragmentation factor (DFF). The sequence of this ... P - K - S - V - K - ... S - P - R - K(18). This ...
Biology Products: